Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...

A team of researchers has developed a "gut-on-chip" (a miniature model of the human intestine on a chip-sized device) capable ...

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...

GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Elizabeth Plimack discussing two abstracts: “Adjuvant nivolumab vs placebo for high-risk ...

The C-POST trial marks the first immunotherapy to show a clear ... have not demonstrated success in the adjuvant treatment of high-risk CSCC. 2 Cemiplimab’s promising results highlight the ...

New research highlights the potential of the novel diagnostic tool iFRET to determine immunotherapy outcomes in stage 2 ...

Adding atezolizumab to adjuvant chemotherapy does not improve outcomes in patients with stage II-III TNBC, phase 3 data suggest.

Patients with stage IA HER2+ breast cancer and smaller tumors had high BCSS rates whether they received adjuvant chemotherapy or not.

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, ...

Aside from the timing, the basic procedures for neoadjuvant and adjuvant chemotherapy ... of a chemotherapy cycle for breast cancer varies but is usually 2 or 3 weeks. The number of infusions ...